Emerging Therapies for Chronic Migraine
Not all chronic migraines are medication-overuse headaches and so the challenge is how to treat them. Currently available pharmacological therapies may be ineffective or they are abandoned because of intolerable side effects. There is still much room for novel therapeutic approaches in those with drug refractory migraine (RM). Occipital nerve stimulation (ONS) and botulinum toxin type A have finally gained a level of evidence based on the results of RCTs and pooled analysis, which by and large have shown at least a modest but valuable therapeutic effect. For a long time, these two approaches were only supported by clinical experience and open-label studies. Considering the disabling nature of migraine disorder, the large prevalence and serious impact on health-related quality of life and health care costs, any degree of response to treatment is acceptable and welcomed by the patient. An important issues for future studies would be better patient selection when finding candidates for each procedure.
KeywordsNeurostimulation Occipital nerve stimulation Chronic migraine Refractory migraine Chronic pain Botulinum toxin type A
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Alberto Proietti Cecchini and Dr. Licia Grazzi each declare no potential conflicts of interest relevant to this article.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 11.•Magis D, Schoenen J. Advances and challenges in neurostimulation for headaches. Lancet Neurol. 2012;11(8), 708–19. This paper provides an exhaustive and updated review of various central and peripheral neuromodulation modalities for treatment of severe intractable primary headache. Google Scholar
- 12.Lipton R, Goadsby PJ, Cady R, et al. PRISM study: occipital nerve stimulation for treatment refractory migraine. Cephalalgia. 2009;29 suppl 1:30 (abstract).Google Scholar
- 21.BOTOX 100 units: UK summary of product characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/112/SPC/BOTOX+100+units/ [Accessed 2011 Nov 1].
- 22.Vistabel: UK summary of product characteristics [online]. Available at: http://www.medicines.org.uk/EMC/medicine/17580/SPC/Vistabel/ [Accessed 2011 Nov 16].
- 23.BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use: US prescribing information. Available at: http://www.allergan.com/assets/pdf/botox_pi.pdf [Accessed 2011 Nov 2].
- 24.BOTOX® Cosmetic (onabotulinumtoxinA) for injection: US prescribing information. Available at: http://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf [Accessed 2011 Nov 16].
- 25.BOTOX 200 units: UK summary of product characteristics. Available at: http://www.medicines.org.uk/EMC/medicine/22562/SPC/Botox+200+units/[Accessed 2011 Nov 1].
- 35.Allergan. A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches [ClinicalTrials.gov identifier NCT00156910]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://clinicaltrials.gov [Accessed 2011 Nov 2].
- 36.Allergan. A study using botulinum toxin type A as headache prophylaxis for migraine patients with frequent headaches [ClinicalTrials.gov identifier NCT00168428]. US National Institutes of Health, ClinicalTrials.gov. Available at: http://clinicaltrials.gov [Accessed 2011 Nov 2].
- 43.•Colloca L, Klinger R, Flor H, Bingel U. Placebo analgesia: psychological and neurobiological mechanisms. Pain. 2013 Apr;154(4):511–4. Placebo effect is not that demon and we should learn how to maximize it in clinical use in the meantime that scientists will work out its role in RCTs. Google Scholar
- 44.Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. Available at: http://guidance.nice.org.uk/ta260. Accessed June 2012.